OHSU
Cancer Centers Nudge Oncologists Toward DPYD Testing as PGx Supporters Push For Guidelines Change
Premium
Several institutions, swayed by PGx experts and advocates, are setting up DPYD testing to avoid deadly chemo toxicities in patients even though the NCCN and FDA don't back it.
NanoString Technologies, OHSU Partner on Breast Cancer Spatial Protein Profiling Assay Development
A new GeoMx Digital Spatial Profiler assay will have up to 30 protein targets and will be validated for potential use as a laboratory-developed test.
Genome Sequencing Increases Sensitivity of Preconception Carrier Screens, CSER Study Finds
Seventy-eight percent of participants had at least one positive carrier screening result and 3.5 percent had a medically actionable secondary finding.
Biological Dynamics Signs Tech Access Deal With OHSU
OHSU researchers will use Biological Dynamics' NanoVerita and ExoVerita lab-on-a-chip systems to develop early cancer detection methods.
Biocept, OHSU Reach Deal on Liquid Biopsy
OHSU was granted the rights to offer Biocept's Target Selector liquid biopsy testing services in Oregon as part of the deal.